• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 4:33:24 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $XTNT alert in real time by email
    SC 13G/A 1 xtant_13gam4dec312020.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

    XTANT MEDICAL HOLDINGS, INC.

    (Name of Issuer)

     

    Common Stock, PAR VALUE $0.000001 per share

    (Title of Class of Securities)

     

    98420P308

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

     

    [   ] Rule 13d-1(b)

    [X] Rule 13d-1(c)

    [   ] Rule 13d-1(d)

      

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

    CUSIP No.  98420P308
    (1) Names of Reporting Persons
      Park West Asset Management LLC  
    (2) Check the Appropriate Box if a Member of a Group (a) [    ]  
      (b) [    ]  
         
    (3) SEC Use Only
    (4) Citizenship or Place of Organization
      Delaware  
    Number of Shares Beneficially Owned By Each Reporting Person With
      (5) Sole Voting Power: 0  
      (6) Shared Voting Power: 0  
      (7) Sole Dispositive Power: 0  
      (8) Shared Dispositive Power: 0  
           
    (9) Aggregate Amount Beneficially Owned by Each Reporting Person
      0  
    (10) Check if the Aggregate Amount  in Row (9) Excludes Certain Shares (See Instructions):
      [    ]  
    (11) Percent of Class Represented by Amount in Row (9)
      0.0%  
    (12) Type of Reporting Person
      IA  
                   

      

    CUSIP No.  98420P308
    (1) Names of Reporting Persons
      Peter S. Park  
    (2) Check the Appropriate Box if a Member of a Group (a) [    ]  
      (b) [    ]  
         
    (3) SEC Use Only
    (4) Citizenship or Place of Organization
      United States of America  
    Number of Shares Beneficially Owned By Each Reporting Person With
      (5) Sole Voting Power: 0  
      (6) Shared Voting Power: 0  
      (7) Sole Dispositive Power: 0  
      (8) Shared Dispositive Power: 0    
           
    (9) Aggregate Amount Beneficially Owned by Each Reporting Person
      0  
    (10) Check if the Aggregate Amount  in Row (9) Excludes Certain Shares (See Instructions):
      [    ]  
    (11) Percent of Class Represented by Amount in Row (9)
      0.0%  
    (12) Type of Reporting Person
      IN  
                   

     
     

     

    CUSIP No.  98420P308
    (1) Names of Reporting Persons
      Park West Investors Master Fund, Limited  
    (2) Check the Appropriate Box if a Member of a Group (a) [    ]  
      (b) [    ]  
         
    (3) SEC Use Only
    (4) Citizenship or Place of Organization
      Cayman Islands  
    Number of Shares Beneficially Owned By Each Reporting Person With
      (5) Sole Voting Power: 0  
      (6) Shared Voting Power:

    0  

     
      (7) Sole Dispositive Power: 0    
      (8) Shared Dispositive Power:

    0  

     
           
    (9) Aggregate Amount Beneficially Owned by Each Reporting Person
      0  
    (10) Check if the Aggregate Amount  in Row (9) Excludes Certain Shares (See Instructions):
      [    ]  
    (11) Percent of Class Represented by Amount in Row (9)
      0.0%*  
    (12) Type of Reporting Person
      CO  
                   

     

     

     

     

     

     
     

     


    Item 1(a).  Name Of Issuer:  Xtant Medical Holdings, Inc. (the “Company”)
       
    Item 1(b).  Address of Issuer’s Principal Executive Offices:
     

    664 Cruiser Lane

    Belgrade, Montana 59714

     

    Item 2(a).  Name of Person Filing:
     

    This report on Schedule 13G (this “Schedule 13G”) is being jointly filed by (i) Park West Asset Management LLC, a Delaware limited liability company (“PWAM”), (ii) Park West Investors Master Fund, Limited, a Cayman Islands exempted company (“PWIMF”) and (iii) Peter S. Park (“Mr. Park” and, collectively with PWAM and PWIMF, the “Reporting Persons”). 

     

    Item 2(b).  Address of Principal Business Office or, if None, Residence:
     

    The address for the Reporting Persons is:  900 Larkspur Landing Circle, Suite 165, Larkspur, California 94939.

     

    Item 2(c).  Citizenship:
     

    PWAM is organized under the laws of the State of Delaware. Mr. Park is a citizen of the United States. PWIMF is a Cayman Islands exempted company.

     

    Item 2(d).  Title of Class of Securities:
      Common Stock, par value $0.000001 per share.
    Item 2(e).  CUSIP No.:
      98420P308
     
     

     

    Item 3.  If This Statement Is Filed Pursuant to Rules 13d-1(b) or 13d-2(b) or (c), Check Whether the Person Filing is a:  
      Not Applicable.  
    Item 4.  Ownership:  
      As reported in the cover pages to this report, the ownership information with respect to each of PWAM and Mr. Park is as follows:  
      (a)     Amount Beneficially Owned: 0     
      (b)    Percent of Class: 0.0%     
      (c)     Number of Shares as to which such person has:      
      (i)     Sole power to vote or to direct the vote: 0    
      (ii)     Shared power to vote or to direct the vote: 0    
      (iii)     Sole power to dispose or to direct the disposition of: 0    
      (iv)     Shared power to dispose or to direct the disposition of: 0    
               

     

      As reported in the cover pages to this report, the ownership information with respect to PWIMF is as follows:  
      (a)     Amount Beneficially Owned: 0      
      (b)    Percent of Class: 0.0%     
      (c)     Number of Shares as to which such person has:      
      (i)     Sole power to vote or to direct the vote: 0    
      (ii)     Shared power to vote or to direct the vote: 0    
      (iii)     Sole power to dispose or to direct the disposition of: 0    
      (iv)     Shared power to dispose or to direct the disposition of: 0    
               

       

     
     

    Item 5.  Ownership of Five Percent or Less of a Class:
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:    [X]
    Item 6.  Ownership of More Than Five Percent on Behalf of Another Person:
      Not Applicable.
    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
      Not Applicable.
    Item 8.  Identification and Classification of Members of the Group:
      Not Applicable.
    Item 9.  Notice of Dissolution of Group:
      Not Applicable.
    Item 10.  Certification:
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

    SIGNATURE

              After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 16, 2021  
         
      PARK WEST ASSET MANAGEMENT LLC  
         
         
      By: /s/ Grace Jimenez  
      Name: Grace Jimenez  
      Title: Chief Financial Officer  
     
         
      PARK WEST INVESTORS MASTER FUND, LIMITED  
           
      By: Park West Asset Management LLC, its Investment Manager  
         
           
           
      By: /s/ Grace Jimenez  
      Name: Grace Jimenez  
      Title: Chief Financial Officer
       

     

          /s/ Peter S. Park  
          Peter S. Park  
             
             

     

    Attention: Intentional misstatements or omissions of fact constitute

    Federal criminal violations (See 18 U.S.C. 1001)

     

     

     

     
     

     

     

    Exhibit Index

     

    Exhibit
     

    99. Joint Filing Agreement dated as of February 14, 2018, by and among Park West Asset Management LLC, Peter S. Park, and Park West Investors Master Fund, Limited (incorporated by reference to Exhibit A to the Schedule 13G filed with the Securities and Exchange Commission on February 14, 2018).

     

     

     

    Get the next $XTNT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XTNT

    DatePrice TargetRatingAnalyst
    12/5/2023$2.00Buy
    BTIG Research
    More analyst ratings

    $XTNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xtant Medical Reports Second Quarter 2025 Financial Results

    Total Revenue of $35.4 Million Increased 18% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Raises FY25 Revenue Guidance to $131-$135 Million, Representing Growth of 11%-15% over FY24 BELGRADE, Mont., Aug. 12, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today reported financial and operating results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Revenue

    8/12/25 7:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xtant Medical to Attend the CG 45th Annual Growth Conference

    BELGRADE, Mont., Aug. 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that Sean Browne, CEO and Scott Neils, CFO will be attending the following upcoming conference: Event: CG 45th Annual Growth ConferenceDate: August 12, 2025 at 3:30pm ETLocation: Boston, MAFormat: 1x1 Meetings & Presentation For more information, please visit:https://wsw.com/webcast/canaccord108/xtnt/2576418  About Xtant Medical Holdings, Inc. X

    8/6/25 4:01:00 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xtant Medical to Announce Second Quarter 2025 Financial Results on August 12, 2025

    BELGRADE, Mont., Aug. 5, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that it will release its financial results for the second quarter ended June 30, 2025, before the start of trading on Tuesday, August 12, 2025. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial officer, will host a conference call at 8:30am ET on that day. Conference Details: Conference Date: Tuesday, August 12

    8/5/25 8:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Xtant Medical with a new price target

    BTIG Research initiated coverage of Xtant Medical with a rating of Buy and set a new price target of $2.00

    12/5/23 8:12:02 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Brandt Kevin D bought $49,837 worth of shares (41,670 units at $1.20), increasing direct ownership by 5% to 815,860 units (SEC Form 4)

    4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

    11/17/23 4:42:41 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Lipschultz Tyler

    3 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

    8/8/25 4:20:04 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Jain Abhinav

    3 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

    8/8/25 4:11:54 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Nantahala Capital Management, Llc claimed ownership of 68,394,000 shares (SEC Form 3)

    3 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

    4/17/25 4:31:14 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    SEC Filings

    View All

    SEC Form 10-Q filed by Xtant Medical Holdings Inc.

    10-Q - Xtant Medical Holdings, Inc. (0001453593) (Filer)

    8/12/25 8:50:26 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xtant Medical Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)

    8/12/25 7:51:29 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xtant Medical Holdings Inc. filed SEC Form 8-K: Other Events

    8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)

    8/8/25 4:15:58 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    Financials

    Live finance-specific insights

    View All

    Xtant Medical Reports Second Quarter 2025 Financial Results

    Total Revenue of $35.4 Million Increased 18% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Raises FY25 Revenue Guidance to $131-$135 Million, Representing Growth of 11%-15% over FY24 BELGRADE, Mont., Aug. 12, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today reported financial and operating results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Revenue

    8/12/25 7:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xtant Medical to Announce Second Quarter 2025 Financial Results on August 12, 2025

    BELGRADE, Mont., Aug. 5, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that it will release its financial results for the second quarter ended June 30, 2025, before the start of trading on Tuesday, August 12, 2025. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial officer, will host a conference call at 8:30am ET on that day. Conference Details: Conference Date: Tuesday, August 12

    8/5/25 8:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xtant Medical Announces Definitive Agreements for the Sale of its Coflex® and CoFix® Spinal Implants and All OUS Businesses to Companion Spine

    Transaction expected to facilitate enhanced focus on Xtant's core businesses Total consideration of approximately $19.2 million allows Xtant to reduce outstanding debt and improve liquidity BELGRADE, Mont., July 8, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that the company has entered into agreements to sell certain Coflex® and CoFix® interlaminar stabilization implant assets and all OUS entities of Paradigm Spine GmbH, to Companion Spine, LLC, a French-American company fully dedicated to posterior dynamic spine stabilizatio

    7/8/25 8:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    Leadership Updates

    Live Leadership Updates

    View All

    Apyx Medical Corporation Announces Board Leadership Transition

    Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead

    5/9/24 7:00:00 AM ET
    $APYX
    $BVS
    $XTNT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Xtant Medical Appoints Lori Mitchell-Keller to Board of Directors

    BELGRADE, Mont., May 18, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Lori Mitchell-Keller to the Company's Board of Directors effective May 16, 2023. Ms. Mitchell-Keller will serve as a member of the Compensation and Audit Committees of the Board of Directors. "We are pleased to welcome Lori to our Board, marking another high-quality independent member addition," said Stavros G. Vizirgianakis, Chairman of Xtant's Board of Directors. "Her deep operations, information technologies, and marketing expertise will be of significant va

    5/18/23 8:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xtant Medical Appoints Mark Schallenberger as Chief Operations Officer

    BELGRADE, Mont., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Mark Schallenberger as Chief Operations Officer, effective January 16, 2023. "We are thrilled to have Mark rejoin the team as we reinvent Xtant," said Sean Browne, President and Chief Executive Officer of Xtant Medical. "In this newly created role, Mark will drive the modernization of our production, lead the optimization of our processes and operations, and support the diversification and development of new product lines. We look forward to Mark's contributio

    1/9/23 8:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Xtant Medical Holdings Inc.

    SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

    9/10/24 4:12:57 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Xtant Medical Holdings Inc. (Amendment)

    SC 13G/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

    2/13/24 5:10:19 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Xtant Medical Holdings Inc. (Amendment)

    SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

    8/3/23 4:59:55 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care